OCULAR THERAPEUTIX, INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Ocular Therapeutix (OCUL) CEO Pravin Dugel sold 21,649 shares at $10.77 each to cover tax obligations, retaining 2,525,429 shares. His spouse transferred 50,092 shares to a trust. OCUL is down 11% YTD but up 12% in 6 months. Analysts set price targets between $18 and $34. The company plans to submit an NDA for AXPAXLI in Q4 2026, with H.C. Wainwright raising its target to $25 and Citizens to $34.
Ocular Therapeutix (OCUL) and 4D Molecular (FDMT) shares rose after EyePoint Pharmaceuticals (EYPT) reported its DURAVYU trial missed its primary goal. Clear Street maintained a 'Buy' rating on OCUL, while B. Riley set a $37 target for FDMT. EYPT's stock fell 67% on the news, with OCUL and FDMT gaining 6% and 19% respectively.
Bristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.
Over the past 7 days, alphai's AI scored 2 news stories mentioning OCUL (OCULAR THERAPEUTIX, INC). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent OCUL coverage spans market movers, financial news and earnings.
In the last 30 days, OCUL insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($322K). The most active reporter was Nayak Sanjay, Chief Strategy Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sell may signal short‑term selling pressure but is a routine tax‑related transaction.
Positive price impact expected from reduced competitive pressure.
Bristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.
Buy rating reinforcement may sustain current bullish bias.
Near-term sentiment tailwind for OCUL tied to reduced competitive read-through in wet AMD implant timelines.
alphai scores every news story that mentions OCUL with an AI model for sentiment and relevance, and aggregates insider trades from OCULAR THERAPEUTIX, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Ocular Therapeutix (OCUL) CEO Pravin Dugel sold 21,649 shares at $10.77 each to cover tax obligations, retaining 2,525,429 shares. His spouse transferred 50,092 shares to a trust. OCUL is down 11% YTD but up 12% in 6 months. Analysts set price targets between $18 and $34. The company plans to submit an NDA for AXPAXLI in Q4 2026, with H.C. Wainwright raising its target to $25 and Citizens to $34.
2 min readOcular Therapeutix (OCUL) and 4D Molecular (FDMT) shares rose after EyePoint Pharmaceuticals (EYPT) reported its DURAVYU trial missed its primary goal. Clear Street maintained a 'Buy' rating on OCUL, while B. Riley set a $37 target for FDMT. EYPT's stock fell 67% on the news, with OCUL and FDMT gaining 6% and 19% respectively.
2 min readBristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.
3 min readModerna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.
3 min readOcular Therapeutix (OCUL) and 4D Molecular (FDMT) rose after EyePoint Pharmaceuticals (EYPT) said its DURAVYU late-stage wet AMD trial missed its main goal versus Eylea. Analysts cited potential competitive relief for OCUL’s Axpaxli and trial design benefits for FDMT’s 4D-150. OCUL gained 6%, FDMT 19%; EYPT shares fell 67%.
5 min readOcular Therapeutix (NASDAQ:OCUL) shares rose 6.32% to $10.81 after EyePoint (NASDAQ:EYPT) reported topline Phase 3 LUGANO results for Duravyu in wet AMD. EyePoint met key secondary endpoints but missed the primary visual acuity endpoint. Analysts said the data may still support filing prospects, while OCUL highlighted its Axpaxli (OTX-TKI) NDA planned for Q4 2026 with SOL-1 and interim SOL-R safety data.
4 min readOcular Therapeutix shares rose 6.3% after EyePoint Pharmaceuticals said its DURAVYU (vorolanib intravitreal insert) failed the primary endpoint in a Phase 3 wet AMD trial (LUGANO) in 211 patients. The miss is seen as a competitive tailwind for Ocular’s AXPAXLI, targeting an NDA in Q4 2026. S&P 500 and Dow were slightly down.
4 min readInvesting.com reports early Monday stock moves ahead of Fed minutes and retail earnings. Micron Technology (MU) rose 4.8% and SpaceX (SPCX) gained 5.41%, while Oracle (ORCL) fell 2.05% and Dell (DELL) dropped 4.1%. It also cites H World Group (HTHT) up 5% on an earnings beat and guidance increase, plus other mid and small-cap movers.
2 min readOcular Therapeutix (NASDAQ:OCUL) shares rose 7.5% after EyePoint Pharmaceuticals (NASDAQ:EYPT) said its DURAVYU missed the primary endpoint in a Phase 3 wet AMD LUGANO trial versus aflibercept. EyePoint cited an asymmetric 9/211 patient subgroup with vision loss unrelated to wet AMD; excluding it, DURAVYU was non-inferior. EyePoint plans an FDA NDA in 1H 2027.
4 min readOcular Therapeutix (OCUL) reported Q2 2026 revenue of $13.48M, essentially flat year over year, while net loss widened to $78.76M. The company also filed an $81.7M shelf registration for up to 10,000,000 common shares for an ESOP-related offering. The update highlights funding and dilution risk for investors.
6 min read
